Skip to main content
Advertising

Originally published September 3, 2014 at 4:41 PM | Page modified September 4, 2014 at 5:22 PM

  • Share:
           
  • Comments
  • Print

Novo Nordisk cuts 63 jobs at Seattle research site

Danish pharmaceutical company Novo Nordisk is eliminating 63 Seattle jobs and closing its inflammation-research center, dealing the second recent blow to the local biotechnology sector from a large drug developer.


Seattle Times deputy business editor

advertising

Danish pharmaceutical company Novo Nordisk is eliminating 63 Seattle jobs and closing its inflammation-research center, dealing the second recent blow to the local biotechnology sector from a large drug developer.

The company is bailing out of inflammation research after its most advanced compound in that area — a drug called anti-IL20 for rheumatoid arthritis — failed to meet its clinical trial goals.

In all, Novo Nordisk will eliminate 400 jobs, primarily in Denmark, China and Seattle, said spokesman Ken Inchausti. Employees here will be out of work by Nov. 3 and will get a severance package and other assistance, he said.

Novo Nordisk also has a diabetes-research center in Seattle that employs nearly 50, and that operation may grow as the company tightens its focus.

“We are going to be continually investing there in diabetes and other therapy areas,” Inchausti said.

Novo Nordisk will retain all the South Lake Union space it leases from Biomed Realty on Fairview Avenue North at Mercer Street, and will take a portion of the new building Biomed is building next door, he said.

The company’s chief scientific officer, Mads Krogsgaard Thomsen, said in a statement Tuesday that “significant unmet opportunities remain within diabetes, including prevention, obesity and diabetes complications. We have therefore decided to further increase our R&D efforts within diabetes, which is our main business area.”

Novo Nordisk opened its inflammation-research center here in 2009. The diabetes center opened in 2012.

In late July, Amgen shocked the biotech industry here by announcing it would close its campus on the Seattle waterfront and a pilot manufacturing plant in Bothell, eliminating 660 jobs, by 2016.

Rami Grunbaum: 206-464-8541 or rgrunbaum@seattletimes.com



Want unlimited access to seattletimes.com? Subscribe now!

Also in Business & Technology

News where, when and how you want it

Email Icon

Where in the world are Seahawks fans?

Where in the world are Seahawks fans?

Put your marker on The Seattle Times interactive map and share your fan story.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►